Association of Gene Polymorphism With Susceptibility to T2DM and the Therapeutic Responses to Exenatide in Chinese Patients With T2DM
Conditions: Type 2 Diabetes Mellitus; Susceptibility, Genetic Interventions: Drug: GLP-1 receptor agonist; Drug: responders group and nonresponders group Sponsors: The Affiliated Hospital of Xuzhou Medical University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 13, 2024 Category: Research Source Type: clinical trials
Exenatide For Reducing the Reinforcing Effects of Cocaine
Conditions: Cocaine Use Disorder Interventions: Drug: Exenatide; Drug: Placebo Sponsors: Christopher Verrico Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - February 12, 2024 Category: Research Source Type: clinical trials
Assessment of Safety, Tolerability and Drug Levels of NPM-119 in Participants With Type 2 Diabetes
Condition: Type 2 Diabetes Interventions: Combination Product: NPM-119 (exenatide implant) low dose; Combination Product: NPM-119 (exenatide implant) high dose; Drug: Bydureon BCise (exenatide extended release) Sponsors: Vivani Medical, Inc; Medpace, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - January 4, 2023 Category: Research Source Type: clinical trials
A Pan-European Post-Authorisation Safety Study: Risk of Pancreatic Cancer Among Type 2 Diabetes Patients Who Initiated Exenatide as Compared With Those Who Initiated Other Non-Glucagon-Like Peptide 1 Receptor Agonists Based Glucose Lowering Drugs
Condition: Pancreatic Cancer Interventions: Drug: Exenatide; Drug: Non-GLP-1 RA based glucose lowering drugs Sponsor: AstraZeneca Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 23, 2022 Category: Research Source Type: clinical trials
